Back to results
US 2018/0002756 A1Published application
Method of treatment based on polymorphisms of the kcnq1 gene
AssigneeVanda Pharmaceuticals Inc.
InventorsCurt D. Wolfgang, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
The invention provides methods for the administration of compounds capable of prolonging a QTc interval and methods for predicting whether an individual is predisposed to such QTc prolongation.
Claims20
A method of treating a patient with a compound capable of prolonging the QT interval, the method comprising:
- determining at least a portion of the patient's KCNQ1 gene sequence;
- and
- administering to the patient a quantity of the compound based on the patient's KCNQ1 gene sequence.
A method of determining whether an individual is predisposed to prolongation of the QTc interval, the method comprising:
- determining at least a portion of an individual's KCNQ1 gene sequence.
A method of treating a patient with a compound capable of prolonging the QT interval, the method comprising:
- characterizing an expression product of the patient's KCNQ1 gene;
- and
- administering to the patient a quantity of the compound based on the characterized expression product.
Dependencies are inferred from the claim text.